The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol
Identifieur interne : 001F81 ( Main/Exploration ); précédent : 001F80; suivant : 001F82The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol
Auteurs : LeWitt [États-Unis] ; David Oakes [États-Unis] ; Lu Cui [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-03.
English descriptors
Abstract
Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to the extent that investigators determined the need for treatment with levodopa. We analyzed DATATOP results to learn if this operationally defined end point could be reproduced from elements of the Unified PD Rating Scale (UPDRS) and other conventional clinical scales. Our analysis involved UPDRS, Schwab and England Activities of Daily Living (S‐E ADL), and Hoehn andYahr (H‐Y) scores when DATATOP subjects reached the study end point. Various UPDRS components were examined, including subscores measuring severity of impaired ADL, bradykinesia, postural instability and gait difficulty, tremor, and rigidity. Data from subjects reaching the end point were compared with assessments of those DATATOP subjects who did not, matched for the same duration of enrollment. All measures showed subjects who reached the end point had significantly greater mean impairment than did controls, although the two groups had substantial overlap. Multivariate analysis by using conditional logistic regression suggested that the end point was determined more by functional (S‐E ADL and the UPDRS ADL scores) than by clinical examination criteria. The method of classification and regression trees suggested a simple decision tree splitting, respectively, on S‐E ADL, UPDRS ADL, H‐Y score, and UPDRS ADL again, with an estimated overall misclassification probability of 18%. We conclude that the DATATOP end point cannot be fully reproduced from the traditional clinical measures, although it can give results that are consistent with these scales in a well‐designed clinical trial.
Url:
DOI: 10.1002/mds.870120208
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol</title>
<author><name sortKey="Lewitt" sort="Lewitt" uniqKey="Lewitt" last="Lewitt">LeWitt</name>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
</author>
<author><name sortKey="Cui, Lu" sort="Cui, Lu" uniqKey="Cui L" first="Lu" last="Cui">Lu Cui</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:36A283FA90DA7215D439244DF12E8AD298B1E5AF</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/mds.870120208</idno>
<idno type="url">https://api.istex.fr/document/36A283FA90DA7215D439244DF12E8AD298B1E5AF/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000535</idno>
<idno type="wicri:Area/Main/Curation">000464</idno>
<idno type="wicri:Area/Main/Exploration">001F81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol</title>
<author><name sortKey="Lewitt" sort="Lewitt" uniqKey="Lewitt" last="Lewitt">LeWitt</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Clinical Neuroscience Center, Sinai Hospital, West Bloomfield, and the Department of Neurology and the Clinical and Cellular Neuroscience Program, Wayne State University School of Medicine, Detroit</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, University of Rochester School of Medicine, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cui, Lu" sort="Cui, Lu" uniqKey="Cui L" first="Lu" last="Cui">Lu Cui</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, University of Rochester School of Medicine, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-03">1997-03</date>
<biblScope unit="volume">12</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="183">183</biblScope>
<biblScope unit="page" to="189">189</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">36A283FA90DA7215D439244DF12E8AD298B1E5AF</idno>
<idno type="DOI">10.1002/mds.870120208</idno>
<idno type="ArticleID">MDS870120208</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>DATATOP</term>
<term>Parkinson's disease</term>
<term>Primary end point</term>
<term>Rating scales</term>
<term>Selegiline</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to the extent that investigators determined the need for treatment with levodopa. We analyzed DATATOP results to learn if this operationally defined end point could be reproduced from elements of the Unified PD Rating Scale (UPDRS) and other conventional clinical scales. Our analysis involved UPDRS, Schwab and England Activities of Daily Living (S‐E ADL), and Hoehn andYahr (H‐Y) scores when DATATOP subjects reached the study end point. Various UPDRS components were examined, including subscores measuring severity of impaired ADL, bradykinesia, postural instability and gait difficulty, tremor, and rigidity. Data from subjects reaching the end point were compared with assessments of those DATATOP subjects who did not, matched for the same duration of enrollment. All measures showed subjects who reached the end point had significantly greater mean impairment than did controls, although the two groups had substantial overlap. Multivariate analysis by using conditional logistic regression suggested that the end point was determined more by functional (S‐E ADL and the UPDRS ADL scores) than by clinical examination criteria. The method of classification and regression trees suggested a simple decision tree splitting, respectively, on S‐E ADL, UPDRS ADL, H‐Y score, and UPDRS ADL again, with an estimated overall misclassification probability of 18%. We conclude that the DATATOP end point cannot be fully reproduced from the traditional clinical measures, although it can give results that are consistent with these scales in a well‐designed clinical trial.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Michigan</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Michigan"><name sortKey="Lewitt" sort="Lewitt" uniqKey="Lewitt" last="Lewitt">LeWitt</name>
</region>
<name sortKey="Cui, Lu" sort="Cui, Lu" uniqKey="Cui L" first="Lu" last="Cui">Lu Cui</name>
<name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:36A283FA90DA7215D439244DF12E8AD298B1E5AF |texte= The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol }}
This area was generated with Dilib version V0.6.23. |